ARIA News 5.01 07/18/2014 04:35:35 Ariad Pharmaceuticals (AR

New Post Public Reply Private Reply Replies (0) Message Board

Jul 18, 2014 at 5:35 AM

Ariad Pharmaceuticals (ARIA) 5.01 $ARIA

Yellen, Icahn Comments Put a Lid on Small-Cap Stocks, May Hurt Larger Market
at The Street - Wed Jul 16, 10:40AM CDT
Recent comments by Fed Chair Janet Yellen and activist investor Carl Icahn have led to selling pressure in small-cap stocks.

ARIAD to Webcast Conference Call on Second Quarter 2014 Financial Results
Business Wire - Wed Jul 16, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its second quarter 2014 financial results on Wednesday, August 6, 2014, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update.

Ariad Stock's Biggest Risk Is Its Only Hope
Brian Wilson, The Motley Fool - Motley Fool - Tue Jul 15, 4:00PM CDT
Overreliance on its blood cancer drug Iclusig (ponatinib) continues to make Ariad Pharmaceuticals an incredibly risky biotech play, despite the mature company's relatively low market cap of $1.1 billion. After a dramatic FDA recall in 2013 based...

Stock Market Today: Social Media, Biotech Suffer as Janet Yellen Shares Concerns on Valuation
at The Street - Tue Jul 15, 3:19PM CDT
Major indices trembled and the Nasdaq slid Tuesday following Fed Chair Janet Yellen's remarks on biotech and social media valuations.

ARIAD Announces Continuation of Iclusig Review under the Article 20 Procedure in Europe
Business Wire - Mon Jul 14, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has provided the Company with a request for limited additional information regarding Iclusig(R) (ponatinib) as part of its ongoing review under the Article 20 referral procedure. The PRAC has requested further information regarding proposed dose modifications after achievement of a response and patient monitoring and details concerning a risk management plan. Following ARIAD's response and input from the agency's Scientific Advisory Group, the Company expects that the PRAC will complete its review and make final recommendations to the Committee for Medicinal Products for Human Use (CHMP) at its meeting in October 2014.

ARIAD Pharmaceuticals (ARIA) Is Water-Logged And Getting Wetter Today
at The Street - Tue Jul 08, 9:39AM CDT
Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

UCB, Dermira Sign Cimzia Dermatology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 5:10PM CDT
UCB SA (UCBJF) and Dermira have entered into a licensing agreement for the development and commercialization of Cimzia in dermatology.

OncoGenex's Apatorsen in Phase II for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 3:30PM CDT
OncoGenex Pharmaceuticals, Inc. (OGXI) announced that apatorsen is in phase II study (Cedar) for advanced squamous cell lung cancer.

Why A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 7:42AM CDT
Why A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock

Alcobra (ADHD) Jumps: Stock Adds 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 8:46AM CDT
Alcobra (ADHD) was a big mover last session, with shares rising nearly 6% on the day.

Zogenix, Inc. (ZGNX) Soars: Stock Adds 18.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 7:51AM CDT
Zogenix, Inc. (ZGNX) was a big mover last session, as its shares rose nearly 19% on the day.

Amgen Gets Breakthrough Therapy Status for Leukemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 4:55PM CDT
Amgen (AMGN) announced that the FDA has granted Breakthrough Therapy Designation to its experimental oncology drug, blinatumomab.

Ariad Pharmaceuticals Up 75.1% Since SmarTrend Uptrend Call (ARIA)
Comtex SmarTrend(R) - Wed Jul 02, 9:35AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on November 22nd, 2013 at $3.67. In approximately 7 months, Ariad Pharmaceuticals has returned 75.07% as of today's recent price of $6.43.

Tesaro (TSRO) in Focus: Stock Moves 8.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 8:46AM CDT
Tesaro (TSRO) was a big mover last session, with shares rising nearly 9% on the day.

Karyopharm Therapeutics (KPTI) in Focus: Stock Goes Down 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 7:59AM CDT
Karyopharm Therapeutics stock fell 5.2% last trading session, reversing its recent trend

Salix Pharmaceuticals (SLXP) Soars: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 7:51AM CDT
Salix Pharmaceuticals Ltd. (SLXP) was a big mover last session, as its shares rose over 11% on the day.

IGI Laboratories (IG) Worth Watching: Stock Rises 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:25AM CDT
IGI Laboratories (IG) was a big mover last session, with shares rising over 6% on the day.

Auxilium Pharmaceuticals (AUXL) Crumbles: Stock Falls by 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 7:59AM CDT
Auxilium Pharmaceuticals has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month

UCB's Vimpat Positive for Partial-Onset Seizures - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 10:50AM CDT
UCB SA (UCBJF) announced positive data from two studies on Vimpat as an early adjunctive therapy in adults suffering from partial-onset seizures.

Pacira's Exparel Positive in Phase IV Studies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 10:30AM CDT
Pacira Pharmaceuticals, Inc. (PCRX) announced significant results from a series of phase IV studies on Exparel.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FIU's PPRIM Device: A New Hope Against Preterm Births

Engineering a Leap in Prenatal Care Talk about flipping the script on prenatal diagnostics. A team from Florida International University (FIU) thinks they've got just the thing to spot early risks of preterm births with a device called PPRIM. It's the brainchild of some sharp minds, including FIU doctoral students Jenny Pei and Amanda Sanchez, and it's come out of FIU's...

Lower Salford Township Upgrades AED Access with Avive

Community Safety Takes Center Stage When it comes to community safety, the urgency can't be overstated, especially in a place like Lower Salford Township, Pennsylvania. This small township with around 16,000 residents has managed to pull off quite the feat in enhancing its emergency response capabilities by deploying 16 Avive Connect AED® devices throughout its police...

Protalix Posts Strong Gains, Eyes Future Milestones

Big Numbers and Bigger Ambitions Protalix BioTherapeutics has come out strong in their third quarter of 2026, showcasing some staggering numbers and laying out ambitious plans for the future. They've managed to pump their revenues up to a cool $75.6 million year-to-date, a leap from $43.6 million in the same period last year. You don't need a crystal ball to see them...

Cell Counting Market Growth: USD 17.71 Billion by 2031

The Cell Counting Surge: Money Talks in Science You can't deny it when the numbers speak—a jump from USD 12.39 billion to USD 17.71 billion by 2031 in the cell counting market means something ain't business as usual. That's a robust 7.40% CAGR folks; it's a field being bombarded with innovation. The spark? Automated and advanced cell analysis technology taking the...

Samsung Display's Cybersecurity Milestone in Auto Sector

Who would've thought we'd be tossing around terms like 'ISO certification' and 'cybersecurity' in the auto sector? Well, welcome to your new reality in 2026, where safeguarding our data is as critical as keeping engines running smoothly. Samsung Display just snagged an ISO/SAE 21434 certification along with an ENX Vehicle Cyber Security label. That's no small...

McEwen Faces Investigation Amid Declining Production

MUX Investors on Alert as Legal Stakes Rise The gold mining world isn't exactly flooded with excitement these days, and McEwen Inc.'s (NYSE: MUX) latest dealings ain't doing much to brighten up the scenery. When their third-quarter gold output took a nosedive—a 23% drop to be exact—it caught more eyes than a bull market will. Production Guidance in Question Now,...

Abbisko's PIMJETMI® Gains FDA Nod, Boosting TGCT Treatment

PIMJETMI® Scores FDA Approval, Expanding Global Reach Well, here's something to chew on over your morning coffee—PIMJETMI® (pimicotinib) just snagged the U.S. FDA's blessing to treat tenosynovial giant cell tumor (TGCT), making it another notch on Abbisko Therapeutics' belt. This approval is a strategic home run for Abbisko and their pals at Merck KGaA, Darmstadt,...

Munters Updates Financial Targets Amid Growth Plans

Munters' Bold New Targets and Strategic Moves Ever feel like you're on a constant treadmill chasing numbers? Munters Group knows the feeling. Over in Stockholm, they've just laid out fresh strategies at their Capital Markets Day—not just any pie-in-the-sky type goals, but heavy hitters that are setting the tone for their future. CEO Stefan Aspman is all geared up,...

Envista's $430M Senior Notes: A Market Move Decoded

Envista on the Move with $430M Notes Ever feel like the market's a bit like a rollercoaster with no brakes? That's kind of where we're at with Envista Holdings Corporation (NYSE: NVST) rolling out this new financial play. They just priced a hefty $430 million in Senior Notes at a solid 6.250% due 2033. In terms of the investment world, that's a pretty big splash. The...

BD Sets Stage for Investor Day in December 2026

BD's Investor Day: A Peek into the Future Say what you will about investor meets, but BD (Becton, Dickinson and Company) throwing its shindig on December 10, 2026, could be a highlight on the calendar if you're eyeing the medical technology sector. Scheduled in New York, this event is gearing up to be a canvas for BD's higher-ups to sketch out their roadmap. If you’re...